Nervonic Acid (cas 26444-06-4) and demyelinating disease

Add time:07/17/2019    Source:sciencedirect.com

Demyelination in adrenoleukodystrophy (ALD) is associated with an accumulation of very long chain saturated fatty acids such as 26:0 stemming from a genetic defect in the peroxisomal beta oxidation system responsible for the chain shortening of these fatty acids. Long chain monoenoic acids such as erucic acid, 22:1(n-9), can normalise elevated serum levels of 26:0 in ALD by depressing their biosynthesis from shorter chain saturated fatty acids. Sphingolipids from post mortem ALD brain have decreased levels of Nervonic Acid (cas 26444-06-4), 24:1(n-9), and increased levels of stearic acid, 18:0. Increased levels of 26:0 are accompanied by decreased nervonic acid biosynthesis in skin fibroblasts from ALD patients. Sphingolipids from post mortem MS brain have the same decreased 24:1(n-9) and increased 18:0 seen in post mortem ALD brain. The 24:1(n-9) content of sphingomyelin is depressed in erythrocytes from multiple sclerosis (MS) patients. Defects in the microsomal biosynthesis of very long chain fatty acids including 24:1(n-9) in ‘jumpy’ and ‘quaking’ mice are accompanied by impaired myelination. An impairment in the provision of nervonic acid in demyelinating diseases is indicated, suggesting that dietary therapy with oils rich in very long chain monenoic acid fatty acids may be beneficial in such conditions.

We also recommend Trading Suppliers and Manufacturers of Nervonic Acid (cas 26444-06-4). Pls Click Website Link as below: cas 26444-06-4 suppliers

Prev:Plasma Fatty Acids in Chronic Kidney Disease: Nervonic Acid (cas 26444-06-4) Predicts Mortality
Next:Nervonic Acid (cas 26444-06-4) is transferred from the maternal diet to milk and tissues of suckling rat pups)